Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting DOI Open Access
Philippe Decruyenaere, Willem Daneels, Annelien Morlion

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(18), С. 9982 - 9982

Опубликована: Сен. 16, 2024

The potential of RNA-based liquid biopsy is increasingly being recognized in diffuse large B-cell lymphoma (DLBCL), the most common subtype non-Hodgkin's lymphoma. This study explores cell-free transcriptome a humanized DLBCL patient-derived tumor xenograft (PDTX) model. Blood plasma samples (n = 171) derived from PDTX model, including 27 (HIS) PDTX, 8 HIS non-PDTX, and 21 non-HIS non-obese diabetic (NOD)-scid IL2Rgnull (NSG) mice were collected during humanization, xenografting, treatment, sacrifice. treated with either rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), CD20-targeted human IFNα2-based AcTaferon combined CHOP (huCD20-Fc-AFN-CHOP), or phosphate-buffered saline (PBS). RNA was extracted using miRNeasy serum/plasma kit sequenced on NovaSeq 6000 platform. sequencing data formalin-fixed paraffin-embedded (FFPE) tissue blood original patient included. Flow cytometry performed immune cells isolated whole blood, spleen, bone marrow. Bulk deconvolution Tabula Sapiens v1 basis matrix. Both R-CHOP huCD20-Fc-AFN-CHOP able to control growth mice. Xenograft volume strongly associated circulating (ctRNA) concentration (

Язык: Английский

The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases DOI Creative Commons
Şeyma Aydın, Selçuk Özdemir, Ahmet Adıgüzel

и другие.

Journal of Molecular Neuroscience, Год журнала: 2025, Номер 75(1)

Опубликована: Март 13, 2025

Abstract Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), and amyotrophic lateral (ALS), are characterized by the progressive gradual degeneration of neurons. The prevalence rates these disorders rise significantly with age. As life spans continue to increase in many countries, number cases is expected grow foreseeable future. Early precise diagnosis, along appropriate surveillance, continues pose a challenge. high heterogeneity neurodegenerative diseases calls for more accurate definitive biomarkers improve clinical therapy. Cell-free DNA (cfDNA), fragmented released into bodily fluids via apoptosis, necrosis, or active secretion, has emerged as promising non-invasive diagnostic tool various diseases. cfDNA can serve an indicator ongoing cellular damage mortality, neuronal loss, may provide valuable insights processes, progression, therapeutic responses. This review will first cover key aspects then examine recent advances its potential use biomarker disorders.

Язык: Английский

Процитировано

1

Liquid biopsy: an emerging field with new opportunities for cancer diagnosis and prognosis DOI Open Access
Dhahiri Saidi Mashausi, Herve Semukunzi

Asia-Pacific Journal of Oncology, Год журнала: 2025, Номер unknown, С. 9 - 17

Опубликована: Янв. 14, 2025

Cancer grades among the deadliest diseases, globally causing death of a over million people each year. Early diagnosis has been considered ideal for efficient treatment as during later stages chances become limited. However, gold standard tissue biopsy various limitation instance, late-stage and its intrusive operation making it unfit repeated sampling. Scientists are passionately looking new technologies techniques cancer prognosis. Liquid emerged diagnostic prognostic tool cancer, that relies on body fluids to identify biomarkers cancer. It offers advantages like non-invasive operation, timely detection, amenable sampling, covers tumor heterogeneity. Wide attention garnered by liquid is undergoing rapid progress in list target biomarkers. The most common circulating cells, DNA, exosomes, educated platelets, non-coding RNAs (miRNA, lncRNA etc.). Each these have unique advantages, indeed technology future with clinical utility. In this article, we tried provide thorough introduction markers, highlighted deployed biopsy, briefly overview their implications indispensable entities diverse types Moreover, discussed prospects revolutionary realm treatment.

Язык: Английский

Процитировано

0

Wide-spectrum profiling of plasma cell-free RNA and the potential for health-monitoring DOI Creative Commons
Xinxin Wang, Shaogang Li,

Rijing Ou

и другие.

RNA Biology, Год журнала: 2025, Номер unknown

Опубликована: Март 20, 2025

Circulating cell-free RNA (cfRNA) has emerged as a promising analyte for disease detection. However, the comprehensive profiling of diverse cfRNA types remains under-characterized. Here, we applied new wide-spectrum sequencing method and simultaneously captured rRNA, tRNA, mRNA, miRNA, lncRNA, all mitochondrial RNA. The compositions, size distributions, highly abundant genes were analyzed each type cfRNA. We depicted cell origin profiles 66 generally healthy individuals found that BMI showed significant impact on kidney-derived proportion. Three with some liver problems identified because relatively high levels hepatocyte-specific abundance different types, including miRNA significantly correlated function test results. individual variances enriched in pathways associated common diseases such diseases, virus infections, cancers, metabolic diseases. This study provided displayed potential biomarker health monitoring.

Язык: Английский

Процитировано

0

Molecular testing and targeting for solid tumors with CNS metastases DOI

Kate E. Therkelsen,

Toni Cao,

Meaghan Roy-O’Reilly

и другие.

Journal of Neuro-Oncology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 3, 2025

Язык: Английский

Процитировано

0

The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology. DOI Creative Commons
Shaivy Malik, Sufian Zaheer

The Journal of Liquid Biopsy, Год журнала: 2025, Номер unknown, С. 100299 - 100299

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

0

Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting DOI Open Access
Philippe Decruyenaere, Willem Daneels, Annelien Morlion

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(18), С. 9982 - 9982

Опубликована: Сен. 16, 2024

The potential of RNA-based liquid biopsy is increasingly being recognized in diffuse large B-cell lymphoma (DLBCL), the most common subtype non-Hodgkin's lymphoma. This study explores cell-free transcriptome a humanized DLBCL patient-derived tumor xenograft (PDTX) model. Blood plasma samples (n = 171) derived from PDTX model, including 27 (HIS) PDTX, 8 HIS non-PDTX, and 21 non-HIS non-obese diabetic (NOD)-scid IL2Rgnull (NSG) mice were collected during humanization, xenografting, treatment, sacrifice. treated with either rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), CD20-targeted human IFNα2-based AcTaferon combined CHOP (huCD20-Fc-AFN-CHOP), or phosphate-buffered saline (PBS). RNA was extracted using miRNeasy serum/plasma kit sequenced on NovaSeq 6000 platform. sequencing data formalin-fixed paraffin-embedded (FFPE) tissue blood original patient included. Flow cytometry performed immune cells isolated whole blood, spleen, bone marrow. Bulk deconvolution Tabula Sapiens v1 basis matrix. Both R-CHOP huCD20-Fc-AFN-CHOP able to control growth mice. Xenograft volume strongly associated circulating (ctRNA) concentration (

Язык: Английский

Процитировано

0